Donor age-adjusted telomere length and outcomes after HSCT in the total population
Characteristics . | All patients . | Telomere-length quartiles . | P . | |||
---|---|---|---|---|---|---|
Q1, < −0.17 . | Q2, −0.26 to 0 . | Q3, 0 to 0.16 . | Q4, > 0.16 . | |||
Neutrophils, > 500/μL | .36 | |||||
No. | 162 | 40 | 41 | 40 | 41 | |
Mean, d | 19.6 | 19.3 | 19.3 | 20.2 | 19.6 | |
95% CI | 18.6-20.6 | 17.7-21 | 17.7-21.4 | 17.8-22.6 | 17.6-21.7 | |
Platelets, > 20 000/μL | .95 | |||||
No. | 148 | 35 | 39 | 38 | 36 | |
Mean, d | 19 | 18.4 | 18.1 | 18.8 | 20.8 | |
95% CI | 17.7-20.3 | 15.8-20.1 | 15.2-21 | 16.2-21.3 | 18-23.6 | |
Acute GVHD | .17 | |||||
No. | 178 | 40 | 43 | 42 | 43 | |
CI at 100 d | 0.45 | 0.45 | 0.47 | 0.29 | 0.51 | |
95% CI | .37-.53 | .31-.62 | .33-.62 | .17-.45 | .37-.67 | |
Chronic GVHD | .25 | |||||
No. | 161 | 40 | 39 | 41 | 41 | |
CI at 24 mo | 0.41 | 0.49 | 0.53 | 0.32 | 0.46 | |
95% CI | .34-.50 | .34-.66 | .38-.70 | .20-.49 | .32-.63 | |
Relapse | .47 | |||||
No. | 147 | 36 | 37 | 40 | 34 | |
CI at 50 mo | 0.21 | 0.25 | 0.23 | 0.17 | 0.23 | |
95% CI | .15-.27 | .12-.45 | .12-.43 | .08-.33 | .12-.42 | |
TRM | .15 | |||||
No. | 178 | 43 | 43 | 43 | 43 | |
CI at 50 mo | 0.24 | 0.26 | 0.30 | 0.14 | 0.14 | |
95% CI | .17-.31 | .12-.40 | .12-.45 | 0-.29 | .03-.25 | |
Survival | .07 | |||||
No. | 178 | 43 | 43 | 43 | 43 | |
CI at 50 mo | 0.64 | 0.63 | 0.49 | 0.77 | 0.69 | |
95% CI | .57-.72 | .46-.75 | .33-.62 | .61-.87 | .53-.81 |
Characteristics . | All patients . | Telomere-length quartiles . | P . | |||
---|---|---|---|---|---|---|
Q1, < −0.17 . | Q2, −0.26 to 0 . | Q3, 0 to 0.16 . | Q4, > 0.16 . | |||
Neutrophils, > 500/μL | .36 | |||||
No. | 162 | 40 | 41 | 40 | 41 | |
Mean, d | 19.6 | 19.3 | 19.3 | 20.2 | 19.6 | |
95% CI | 18.6-20.6 | 17.7-21 | 17.7-21.4 | 17.8-22.6 | 17.6-21.7 | |
Platelets, > 20 000/μL | .95 | |||||
No. | 148 | 35 | 39 | 38 | 36 | |
Mean, d | 19 | 18.4 | 18.1 | 18.8 | 20.8 | |
95% CI | 17.7-20.3 | 15.8-20.1 | 15.2-21 | 16.2-21.3 | 18-23.6 | |
Acute GVHD | .17 | |||||
No. | 178 | 40 | 43 | 42 | 43 | |
CI at 100 d | 0.45 | 0.45 | 0.47 | 0.29 | 0.51 | |
95% CI | .37-.53 | .31-.62 | .33-.62 | .17-.45 | .37-.67 | |
Chronic GVHD | .25 | |||||
No. | 161 | 40 | 39 | 41 | 41 | |
CI at 24 mo | 0.41 | 0.49 | 0.53 | 0.32 | 0.46 | |
95% CI | .34-.50 | .34-.66 | .38-.70 | .20-.49 | .32-.63 | |
Relapse | .47 | |||||
No. | 147 | 36 | 37 | 40 | 34 | |
CI at 50 mo | 0.21 | 0.25 | 0.23 | 0.17 | 0.23 | |
95% CI | .15-.27 | .12-.45 | .12-.43 | .08-.33 | .12-.42 | |
TRM | .15 | |||||
No. | 178 | 43 | 43 | 43 | 43 | |
CI at 50 mo | 0.24 | 0.26 | 0.30 | 0.14 | 0.14 | |
95% CI | .17-.31 | .12-.40 | .12-.45 | 0-.29 | .03-.25 | |
Survival | .07 | |||||
No. | 178 | 43 | 43 | 43 | 43 | |
CI at 50 mo | 0.64 | 0.63 | 0.49 | 0.77 | 0.69 | |
95% CI | .57-.72 | .46-.75 | .33-.62 | .61-.87 | .53-.81 |
Q indicates quartile; CI, confidence interval; and TRM, treatment-related mortality.